Namenda XR

See also: Generic Namenda

Namenda XR is a brand name of memantine, approved by the FDA in the following formulation(s):

NAMENDA XR (memantine hydrochloride - capsule, extended release; oral)

• 
  Manufacturer: FOREST LABS
  
  Approval date: June 21, 2010
  
  Strength(s): 14MG, 21MG, 28MG ^[RLD], 7MG
  

Has a generic version of Namenda XR been approved?

No. There is currently no therapeutically equivalent version of Namenda XR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Namenda XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Adamantane derivatives in the prevention and treatment of cerebral ischemia
  Patent 5,061,703
  Issued: October 29, 1991
  Inventor(s): Bormann; Joachim & Gold; Markus R. & Schatton; Wolfgang
  Assignee(s): Merz + Co. GmbH & Co.
  A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.
  
  Patent expiration dates:
  
  
  • April 11, 2015
    
    ✓ 
    Patent use: TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
  
  



• 
  Modified release formulations of memantine oral dosage forms
  Patent 8,039,009
  Issued: October 18, 2011
  Inventor(s): Rastogi; Suneel K. & Rao; Niranjan & Periclou; Antonia & Abramowitz; Wattanaporn & Dedhiya; Mahendra G. & Mahashabde; Shashank
  Assignee(s): Forest Laboratories Holdings Limited
  The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
  
  Patent expiration dates:
  
  
  • March 24, 2029
    
    ✓ 
    Patent use: TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 21, 2013 - NEW DOSAGE FORM
  
  

See also...

• Namenda XR Advanced Consumer Information (Micromedex)
• Memantine Consumer Information (Wolters Kluwer)
• Memantine Solution Consumer Information (Wolters Kluwer)
• Memantine Tablets Consumer Information (Wolters Kluwer)
• Memantine Consumer Information (Cerner Multum)
• Memantine Advanced Consumer Information (Micromedex)
• Memantine Hydrochloride AHFS DI Monographs (ASHP)